IMT-009 is under clinical development by Immunitas Therapeutics and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According to GlobalData, Phase II drugs for Cutaneous Squamous Cell Carcinoma (cSCC) have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMT-009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - IMT-009 in Cutaneous Squamous Cell Carcinoma (cSCC)

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IMT-009 overview

IMT-009 is under development for the treatment solid tumors and hematological malignancies including squamous or non-squamous non-small cell lung cancer, head and neck squamous cell carcinoma, triple negative breast cancer, cutaneous squamous cell carcinoma, hormone receptor positive breast cancer, small bowel carcinoma, esophageal cancer, colorectal cancer, diffuse large b cell lymphoma, Hodgkin lymphoma, follicular lymphoma. It is administered through intravenous route. IMT-009, acts by targeting CD161. The therapeutic candidate is being developed based on single cell genomics platform. follicular lymphoma
It was under development for the treatment of t-cell lymphoma.

Immunitas Therapeutics overview

Immunitas Therapeutics discovers and develops targeted treatments for various oncology indications. The company is investigating antibodies and biomarkers to treat cancer. It utilizes a single-cell genomics platform to develop drugs by analyzing the biology of immune cells in human tumors. The company’s funding partners include Alexandria Real Estate Equities Inc, Evotec AG, Longwood Fund and M Ventures, among others. Immunitas Therapeutics is headquartered in Waltham, Massachusetts, the US

For a complete picture of IMT-009’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.